MAPT and Alzheimer disease: Initially, the brain can cope and compensate for the neurotoxicity of this process in what is called “preclinical AD.” However, often linked to the spreading of tau pathology in cortical regions, symptoms start to appear in what is called “mild cognitive impairment” or “prodromal AD.” The cognitive function progressively deteriorates, leading to dementia in a few years.